Lupin Divests U.S. Commercial Women’s Health Specialty Business to Evofem, including SOLOSEC
MUMBAI, India and NAPLES, Fla. and SAN DIEGO, July 15, 2024 /PRNewswire/ — Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced today that it has divested its U.S. Commercial Women’s Health Specialty Business to Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem), a U.S. biopharmaceutical company focused exclusively on Women’s Health. Lupin’s U.S. Commercial Women’s Health Specialty Business is primarily focused on commercializing SOLOSEC® (secnidazole) 2g oral granules. This FDA-approved single-dose antimicrobial agent provides a complete course of therapy for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections.
Related news for (EVFM)
- FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences’ “One and Done” Oral Treatment for Bacterial Vaginosis and Trichomoniasis
- Evofem Biosciences to Present at Emerging Growth Conference
- Windtree Therapeutics Strikes Deal to Source PHEXXI, Signaling Revenue-Driven Pivot
- Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
- Evofem Biosciences Announces Financial Results for the Second Quarter of 2024